Boston Scientific reported $5.065 billion in net sales for the third quarter of 2025, driven largely by demand for cardiovascular devices.
The company’s cardiovascular segment grew 22.4% year over year on a reported basis, with strong performance from both cardiology and peripheral interventions. U.S. sales rose 27% overall, according to an Oct. 22 news release.
GAAP net income attributable to common stockholders reached $755 million, or $0.51 per share, up from $469 million and $0.32 per share a year prior. Adjusted earnings were $0.75 per share.
The devicemaker also raised its full-year guidance, projecting adjusted earnings of $3.02 to $3.04 per share and organic sales growth of 15.5%.
